Latest Information Update: 07 Apr 1999
At a glance
- Originator AstraZeneca
- Class Antiglaucomas
- Mechanism of Action Beta-adrenergic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed.
- 30 May 1995 New profile
- 30 May 1995 Discontinued-Preclinical for Glaucoma in Sweden (Unknown route)